Current management of sickle cell anemia

Patrick T. McGann, Alecia C. Nero, Russell E. Ware

Research output: Contribution to journalArticle

15 Citations (Scopus)

Abstract

Proper management of sickle cell anemia (SCA) begins with establishing the correct diagnosis early in life, ideally during the newborn period. The identification of affected infants by neonatal screening programs allows early initiation of prophylactic penicillin and pneumo-coccal immunizations, which help prevent overwhelming sepsis. Ongoing education of families promotes the early recognition of disease-released complications, which allows prompt and appropriate medical evaluation and therapeutic intervention. Periodic evaluation by trained specialists helps provide comprehensive care, including transcranial Doppler examinations to identify children at risk for primary stroke, plus assessments for other paren-chymal organ damage as patients become teens and adults. Treatment approaches that previously highlighted acute vaso-occlusive events are now evolving to the concept of preventive therapy. Liberalized use of blood transfusions and early consideration of hydroxy-urea treatment represent a new treatment paradigm for SCA management.

Original languageEnglish (US)
JournalCold Spring Harbor perspectives in medicine
Volume3
Issue number8
DOIs
StatePublished - Aug 2013

Fingerprint

Sickle Cell Anemia
Immunization
Hydroxyurea
Penicillins
Screening
Blood
Education
Therapeutics
Neonatal Screening
Blood Transfusion
Sepsis
Stroke
Newborn Infant

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Current management of sickle cell anemia. / McGann, Patrick T.; Nero, Alecia C.; Ware, Russell E.

In: Cold Spring Harbor perspectives in medicine, Vol. 3, No. 8, 08.2013.

Research output: Contribution to journalArticle

McGann, Patrick T. ; Nero, Alecia C. ; Ware, Russell E. / Current management of sickle cell anemia. In: Cold Spring Harbor perspectives in medicine. 2013 ; Vol. 3, No. 8.
@article{17b867fd76b148dbb07b937408410110,
title = "Current management of sickle cell anemia",
abstract = "Proper management of sickle cell anemia (SCA) begins with establishing the correct diagnosis early in life, ideally during the newborn period. The identification of affected infants by neonatal screening programs allows early initiation of prophylactic penicillin and pneumo-coccal immunizations, which help prevent overwhelming sepsis. Ongoing education of families promotes the early recognition of disease-released complications, which allows prompt and appropriate medical evaluation and therapeutic intervention. Periodic evaluation by trained specialists helps provide comprehensive care, including transcranial Doppler examinations to identify children at risk for primary stroke, plus assessments for other paren-chymal organ damage as patients become teens and adults. Treatment approaches that previously highlighted acute vaso-occlusive events are now evolving to the concept of preventive therapy. Liberalized use of blood transfusions and early consideration of hydroxy-urea treatment represent a new treatment paradigm for SCA management.",
author = "McGann, {Patrick T.} and Nero, {Alecia C.} and Ware, {Russell E.}",
year = "2013",
month = "8",
doi = "10.1101/cshperspect.a011817",
language = "English (US)",
volume = "3",
journal = "Cold Spring Harbor perspectives in medicine",
issn = "2157-1422",
publisher = "Cold Spring Harbor Laboratory Press",
number = "8",

}

TY - JOUR

T1 - Current management of sickle cell anemia

AU - McGann, Patrick T.

AU - Nero, Alecia C.

AU - Ware, Russell E.

PY - 2013/8

Y1 - 2013/8

N2 - Proper management of sickle cell anemia (SCA) begins with establishing the correct diagnosis early in life, ideally during the newborn period. The identification of affected infants by neonatal screening programs allows early initiation of prophylactic penicillin and pneumo-coccal immunizations, which help prevent overwhelming sepsis. Ongoing education of families promotes the early recognition of disease-released complications, which allows prompt and appropriate medical evaluation and therapeutic intervention. Periodic evaluation by trained specialists helps provide comprehensive care, including transcranial Doppler examinations to identify children at risk for primary stroke, plus assessments for other paren-chymal organ damage as patients become teens and adults. Treatment approaches that previously highlighted acute vaso-occlusive events are now evolving to the concept of preventive therapy. Liberalized use of blood transfusions and early consideration of hydroxy-urea treatment represent a new treatment paradigm for SCA management.

AB - Proper management of sickle cell anemia (SCA) begins with establishing the correct diagnosis early in life, ideally during the newborn period. The identification of affected infants by neonatal screening programs allows early initiation of prophylactic penicillin and pneumo-coccal immunizations, which help prevent overwhelming sepsis. Ongoing education of families promotes the early recognition of disease-released complications, which allows prompt and appropriate medical evaluation and therapeutic intervention. Periodic evaluation by trained specialists helps provide comprehensive care, including transcranial Doppler examinations to identify children at risk for primary stroke, plus assessments for other paren-chymal organ damage as patients become teens and adults. Treatment approaches that previously highlighted acute vaso-occlusive events are now evolving to the concept of preventive therapy. Liberalized use of blood transfusions and early consideration of hydroxy-urea treatment represent a new treatment paradigm for SCA management.

UR - http://www.scopus.com/inward/record.url?scp=84881069732&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84881069732&partnerID=8YFLogxK

U2 - 10.1101/cshperspect.a011817

DO - 10.1101/cshperspect.a011817

M3 - Article

C2 - 23709685

AN - SCOPUS:84881069732

VL - 3

JO - Cold Spring Harbor perspectives in medicine

JF - Cold Spring Harbor perspectives in medicine

SN - 2157-1422

IS - 8

ER -